Key Takeaways
- •The peptide therapeutics sector is witnessing a wave of specialization as contract research organizations adapt to the unique demands of these molecules.
- •This move reflects a broader industry trend: as blockbuster peptide drugs face patent expirations and the pipeline of no
- •The new service line integrates several components essential for peptide clinical trials.
Oxurion Expands Clinical Services for GLP-1 and Peptide-Based Therapies
The peptide therapeutics sector is witnessing a wave of specialization as contract research organizations adapt to the unique demands of these molecules. Oxurion, through its subsidiary Axiodis, has launched a new suite of services focused on biometrics, clinical data management, biostatistics, and regulatory-compliant data workflows. These offerings are specifically designed to support peptide bioequivalence studies and clinical development programs for GLP-1 therapies, biosimilars, and next-generation peptides.
This move reflects a broader industry trend: as blockbuster peptide drugs face patent expirations and the pipeline of novel peptides expands, CROs are building dedicated infrastructure to handle the complex data and regulatory requirements of these therapies.
Expanding Biometrics and Data Services for Peptide Therapies
The new service line integrates several components essential for peptide clinical trials. Oxurion now offers specialized support in biometrics, which encompasses statistical analysis of biological data, and biostatistics, the application of statistical methods to medical research. Clinical data management services include database building, validation, and electronic case report form (eCRF) design and management. Regulatory-quality data workflows ensure that data collection and processing meet the standards required for submission to health authorities.
These services are particularly relevant for bioequivalence studies, where generic or biosimilar peptide products must demonstrate comparable pharmacokinetics and pharmacodynamics to the reference drug. The complexity of peptide molecules, which can vary in structure, stability, and immunogenicity, demands rigorous data handling and analysis. By offering a dedicated platform for such work, Oxurion aims to streamline the development pathway for companies working on GLP-1 agonists and other peptide-based therapeutics.
The Exagis Platform: Supporting Global Clinical Data Management
Central to the new offering is the proprietary Exagis platform, which is currently deployed in 12 countries. According to the company, Exagis supports over 7,000 patient files across its network. The platform covers a comprehensive range of functions: clinical data management, biometrics and biostatistics, eCRF design and management, regulatory quality data workflows, database building and validation, as well as statistical analysis and reporting.
The use of a unified digital platform allows for consistent data collection across multiple sites and countries, reducing the risk of discrepancies and improving the speed of data cleaning and analysis. For peptide therapies, where endpoints often involve precise measurements of hormone levels, glucose regulation, or body weight, the ability to manage large volumes of longitudinal data is critical. The Exagis platform's deployment across national borders also facilitates multi-center international trials, which are common for GLP-1 drugs given their global market potential.
GLP-1 Market Dynamics and Patent Expirations
The timing of Oxurion's service expansion aligns with major shifts in the GLP-1 market. Patents on key molecules such as semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, are approaching expiration. This is accelerating the development of biosimilars, generics, and next-generation peptide therapies that aim to improve upon existing treatments in terms of dosing frequency, tolerability, or efficacy.
Biosimilars for peptide drugs present unique challenges compared to small-molecule generics. Because peptides are larger, more complex molecules often produced through recombinant DNA technology, demonstrating similarity to the reference product requires extensive analytical and clinical data. Bioequivalence studies for these agents must account for factors such as aggregation, degradation products, and immunogenicity. The specialized biometrics and data management services now offered by Oxurion are tailored to handle these intricacies.
The expiration of semaglutide patents is expected to open the door for multiple competitors in the GLP-1 space, potentially reducing prices and expanding access. However, the regulatory pathway for peptide biosimilars remains stringent, and companies will need robust clinical data packages to gain approval. Dedicated CRO support in biostatistics and regulatory workflows can help sponsors navigate this process more efficiently.
Surge in Peptide Clinical Trials and Market Projections
The expansion of peptide research is not limited to GLP-1 agonists. According to an analysis of data from ClinicalTrials.gov, the number of phase I clinical trials involving peptides increased from 18 in 2023 to 137 in 2025. This nine-fold rise indicates a rapidly growing pipeline of novel peptide candidates moving into early human testing. Currently, over 2,700 peptide-related studies are registered globally, covering a wide range of indications including metabolic diseases, oncology, infectious diseases, and neurology.
These figures reflect the broader recognition of peptides as a versatile therapeutic modality. Peptides occupy a middle ground between small molecules and biologics, offering high target specificity with relatively low immunogenicity. Advances in peptide synthesis, delivery technologies, and formulation have overcome many historical barriers, such as rapid degradation in the gastrointestinal tract and short half-lives.
Industry forecasts suggest that the global market for GLP-1 receptor agonists alone will surpass $150 billion by 2029. This projection is driven by the expanding use of these drugs beyond type 2 diabetes and obesity, into areas such as non-alcoholic steatohepatitis (NASH), cardiovascular disease, and even addiction disorders. The sheer scale of the market opportunity is prompting both large pharmaceutical companies and specialized biotech firms to invest heavily in next-generation GLP-1 peptides and fixed-dose combinations.
Strategic Moves in the CRO Sector
Oxurion is concurrently pursuing another strategic acquisition in the contract research organization sector. If realized, this transaction would complement the group's existing expertise in biometrics and data management by adding capabilities in clinical operations and monitoring. Such integration would broaden the service offering available to pharmaceutical and biotechnology companies, providing end-to-end clinical development support under one umbrella.
The CRO market itself is undergoing consolidation, as sponsors increasingly prefer partners that can handle everything from trial design and site selection to data analysis and regulatory submission. By adding clinical operations expertise, Oxurion would position itself to compete more directly with larger CROs that offer full-service packages. The focus on peptide and GLP-1 therapies gives the company a differentiated niche in a rapidly growing segment of the drug development landscape.
Clinical operations and monitoring involve the day-to-day management of trial sites, patient recruitment, data collection oversight, and adherence to good clinical practice (GCP) guidelines. For peptide studies, which often require frequent injections or monitoring of metabolic parameters, having experienced clinical monitors who understand the specific challenges of these protocols can improve data quality and patient compliance.
Frequently Asked Questions
Q: What types of studies are supported by the new services from Oxurion?
A: The services are intended for peptide bioequivalence studies and clinical development programs for GLP-1 therapies, biosimilars, and next-generation peptides. They cover biometrics, clinical data management, biostatistics, and regulatory-compliant data workflows.
Q: How does the Exagis platform function in multinational trials?
A: Exagis is deployed in 12 countries and supports over 7,000 patient files. It handles clinical data management, eCRF design, database building and validation, statistical analysis, and regulatory quality workflows. The platform enables consistent data collection and processing across multiple sites and countries.
Q: Why is the GLP-1 market expected to grow so rapidly?
A: Patents on key molecules like semaglutide are expiring, opening the door for biosimilars and generics. Additionally, indications for GLP-1 receptor agonists are expanding beyond diabetes and obesity into areas such as NASH and cardiovascular disease. Industry forecasts predict the global market will exceed $150 billion by 2029.
Q: What is the significance of the increase in peptide phase I trials from 18 to 137 between 2023 and 2025?
A: This nine-fold increase signals a surge in early-stage peptide drug development. It reflects technological advances in peptide synthesis and delivery, as well as growing interest in targeting a wide range of diseases. Over 2,700 peptide-related studies are currently registered globally, indicating a robust pipeline.